Working Together to Find a Cure     Print Page | Close Window

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016

June 6, 2018: Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference

May 31, 2018: Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio

May 18, 2018: Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting

May 17, 2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting

May 14, 2018: Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors

May 11, 2018: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights

May 8, 2018: Abeona Therapeutics Announces Upcoming Presentations

April 23, 2018: Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA

April 20, 2018: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

April 2, 2018: Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

March 16, 2018: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

March 15, 2018: Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

February 21, 2018: Abeona Therapeutics Announces Upcoming Conference Participation

February 12, 2018: Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease

February 8, 2018: Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA

February 7, 2018: Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial

February 2, 2018: Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium

January 29, 2018: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa